Assembly Biosciences reported Q2 2024 financial results with collaboration revenue of $8.5 million from the Gilead agreement, compared to no revenue in Q2 2023. Net loss was $11.2 million or $1.98 per share, improved from a $16.9 million loss or $3.88 per share in the prior year period. Research and development expenses increased 30% to $16.3 million due to advancement of key programs.The company ended the quarter with $109.2 million in cash, cash equivalents and marketable securities. During Q2, Assembly raised $12.4 million through a registered direct offering and private placement, including shares and warrants sold to Gilead to maintain its 19.9% ownership stake. General and administrative expenses decreased 10% to $4.5 million.Assembly advanced multiple clinical programs, including initiating Phase 1 studies for ABI-5366 in recurrent genital herpes and ABI-4334 for chronic HBV infection. The company expects to begin additional Phase 1 trials by year-end for ABI-6250 in HDV and ABI-1179 in recurrent genital herpes. Management believes current funding will support operations into 2026.

Assembly Biosciences reported Q2 2024 financial results with collaboration revenue of $8.5 million from the Gilead agreement, compared to no revenue in Q2 2023. Net loss was $11.2 million or $1.98 per share, improved from a $16.9 million loss or $3.88 per share in the prior year period. Research and development expenses increased 30% to $16.3 million due to advancement of key programs.The company ended the quarter with $109.2 million in cash, cash equivalents and marketable securities. During Q2, Assembly raised $12.4 million through a registered direct offering and private placement, including shares and warrants sold to Gilead to maintain its 19.9% ownership stake. General and administrative expenses decreased 10% to $4.5 million.Assembly advanced multiple clinical programs, including initiating Phase 1 studies for ABI-5366 in recurrent genital herpes and ABI-4334 for chronic HBV infection. The company expects to begin additional Phase 1 trials by year-end for ABI-6250 in HDV and ABI-1179 in recurrent genital herpes. Management believes current funding will support operations into 2026.